Vaxart Director reported grant of 39,400 shares upon RSU vesting, option for 78,700 shares, and sale of 10 shares at $13.73 in Form 4 filing

Vaxart's director recently reported significant stock transactions in a Form 4 filing with the SEC. The filing disclosed a grant of 39,400 shares upon the vesting of restricted stock units, with an option for 78,700 shares that will also vest by July 16, 2027.²⁴

The director sold 10 shares at a price of $13.73, reflecting a strategic move in stock management. The shares from the restricted stock units are set to vest on the earlier of the date immediately prior to the 2027 annual meeting of stockholders or on July 16, 2027, marking the first anniversary of the grant.³

This activity is part of Vaxart's ongoing efforts to manage its equity compensation and align the interests of its leadership with those of shareholders. The reported transactions indicate a proactive approach to stock ownership and potential liquidity events for the director.

The Form 4 filing is a standard requirement for reporting changes in beneficial ownership, ensuring transparency in the company's operations and governance.

As Vaxart continues to navigate the complexities of the biotech industry, such disclosures are crucial for maintaining investor confidence and regulatory compliance.